European Heart Journal · 2016 · 235 citations · 24 references
MedicineCardiologyClinical CardiologyElectronic Health RecordsInterventional CardiologyAblation TherapyAtrial FibrillationCardiac CatheterizationCatheter AblationAtrial Fibrillation ComplicationsComplication Rate AnalysisComplication Rate MeasurementComplication Rate MonitoringIn-hospital MortalityPostoperative Atrial FibrillationPulmonary Vein IsolationSurgical Ablation
AIMS: The ESC-EHRA Atrial Fibrillation Ablation Long-Term registry is a prospective, multinational study that aims at providing an accurate picture of contemporary real-world ablation for atrial fibrillation (AFib) and its outcome. METHODS AND RESULTS: A total of 104 centres in 27 European countries participated and were asked to enrol 20-50 consecutive patients scheduled for first and re-do AFib ablation. Pre-procedural, procedural and 1-year follow-up data were captured on a web-based electronic case record form. Overall, 3630 patients were included, of which 3593 underwent an AFib ablation (98.9%). Median age was 59 years and 32.4% patients had lone atrial fibrillation. Pulmonary vein isolation was attempted in 98.8% of patients and achieved in 95-97%. AFib-related symptoms were present in 97%. In-hospital complications occurred in 7.8% and one patient died due to an atrioesophageal fistula. One-year follow-up was performed in 3180 (88.6%) at a median of 12.4 months (11.9-13.4) after ablation: 52.8% by clinical visit, 44.2% by telephone contact and 3.0% by contact with the general practitioner. At 12-months, the success rate with or without antiarrhythmic drugs (AADs) was 73.6%. A significant portion (46%) was still on AADs. Late complications included 14 additional deaths (4 cardiac, 4 vascular, 6 other causes) and 333 (10.7%) other complications. CONCLUSION: AFib ablation in clinical practice is mostly performed in symptomatic, relatively young and otherwise healthy patients. Overall success rate is satisfactory, but complication rate remains considerable and a significant portion of patients remain on AADs. Monitoring after ablation shows wide variations. Antithrombotic treatment after ablation shows insufficient guideline-adherence.
24
Erik von Elm, Douglas G. Altman, Matthias Egger et al. · The Lancet · 2007 · 18.7K citations · Full text
Public Health, Public Health Practice, Epidemiologic Methods +10
A. John Camm, Paulus Kirchhof, Gregory Y.H. Lip et al. · European Heart Journal · 2010 · 5.9K citations · Full text
Karl Heinz Kuck, Riccardo Cappato, Josép Brugada et al. · EP Europace · 2012 · 2.7K citations · Full text
Medicine, Cardiology, Surgery +11